Clinical Trial Detail

NCT ID NCT03430843
Title A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

esophagus squamous cell carcinoma

Therapies

Docetaxel

Paclitaxel

Tislelizumab

Irinotecan

Age Groups: senior adult

No variant requirements are available.